Clinical trials: Substance-Related Disorder
Alcohol-Related Disorders, Anxiety Disorders
Psychosocial and Medication Treatment for Anxiety in Alcoholism
The proposed project is written as a "typical clinical practice" test and is a fully-controlled trial of a combined anxiety-focused CBT and pharmacotherapy (venlafaxine; CBT-VEN) delivered for patients with comorbid alcohol-use…
- Trial name
- NCT00248612
- Testing
- Venlafaxine, CBT, Progressive muscle relaxation therapy (PMR)
- Where
- 2 sites in United States
- Volunteers
- 162 people
- Sponsor
- Boston Medical Center
Cannabis-Related Disorder, Substance-Related Disorders
First Episode Schizophrenia and Cannabis-Related Disorder Study
Many individuals with schizophrenia abuse cannabis at the onset of their illness, portending a poorer course of illness and poorer treatment response.
- Conditions
- Cannabis-Related Disorder, Substance-Related Disorders, Schizophrenia, Psychotic Disorders
- Trial name
- NCT00573287
- Testing
- clozapine, risperidone
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Alcohol Dependence, Stress Disorders, Post-Traumatic
Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).
Prazosin is an alpha-1 adrenergic receptor antagonist that has been used successfully in the treatment of trauma nightmares and sleep disturbance in combat veterans with PTSD, and alcohol dependence.
- Trial name
- NCT00744055
- Testing
- Prazosin
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Yale University
Smoking, Nicotine Dependence
Naltrexone and Varenicline: Weight Gain and Tolerability in Cigarette Smokers
The purpose of this study is to determine whether the combination of naltrexone (Depade) and varenicline (Chantix) minimizes post-smoking cessation weight gain and how well the combination is tolerated.
- Trial name
- NCT00502216
- Testing
- Naltrexone, Varenicline
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Yale University
Alcohol-Related Disorders, Alcohol Dependence
Acamprosate to Reduce Symptoms of Alcohol Withdrawal
This study will examine whether a new drug called acamprosate can be helpful for alcohol withdrawal, a result of drinking high amounts of alcohol for long periods of time.
- Conditions
- Alcohol-Related Disorders, Alcohol Dependence, Alcoholism, Healthy Volunteer
- Trial name
- NCT00106106
- Testing
- NMR-spectroscopy, Oral acamprosate
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Alcohol Use Disorder, Anxiety Disorders
Transdiagnostic CBT for Comorbid Alcohol Use and Anxiety Disorders
Almost 18 million US adults have alcohol use disorders (AUD), with one third of these individuals also diagnosed with anxiety disorders (AXD).
- Trial name
- NCT03230006
- Testing
- Unified Protocol for Transdiagnostic Treatment of Emotional Disorders, Take Control
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Boston University Charles River Campus
Alcohol Dependence
Gabapentin for Abstinence Initiation in Alcohol Dependence
Primary Hypotheses: 1. Gabapentin will significantly reduce alcohol consumption and promote abstinence as compared to placebo. The primary outcome measure will be the number of the heavy drinking days (defined as any day where…
- Trial name
- GAINS (NCT01141049)
- Testing
- Gabapentin
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- New York State Psychiatric Institute
Pain
Opioid and Cannabinoid Pharmacokinetic Interactions
We are conducting a study to assess whether smoking marijuana affects the safety of prescribed opioids in patients treated for chronic pain.
- Trial name
- NCT00308555
- Testing
- Cannabis
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, San Francisco
HIV/AIDS, Smoking Cessation
Learn to Quit-HIV Pilot Study
The study team will conduct a feasibility, acceptability, and preliminary efficacy trial comparing Learn to Quit-HIV (n=30) to an app based on U.S.
- Conditions
- HIV/AIDS, Smoking Cessation, Tobacco Use Disorder
- Trial name
- NCT04609514
- Testing
- Learn to Quit-HIV, QuitGuide, Nicotine patch
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Duke University
Hepatitis, Alcoholic
Pentoxifylline for Acute Alcoholic Hepatitis (AAH)
The goal of this study is to demonstrate the effectiveness of pentoxifylline compared to placebo in AAH while studying putative mechanisms that are plausible and testable.
- Trial name
- NCT00205049
- Testing
- pentoxifylline
- Volunteers
- 4 people
- Sponsor
- University of Wisconsin, Madison
Cocaine Addiction
Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving
We propose that the systemic administration of lidocaine following the induction of cue-induced craving, relative to saline plus cue-induced craving or lidocaine without cue-induced craving, will block the reconsolidation of cue…
- Trial name
- LIDO (NCT01929343)
- Testing
- lidocaine following cue-induced craving, lidocaine following neutral stimulus, saline
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Bryon Adinoff
Substance Use Disorders
Behavioral Treatment of Adolescent Substance Use
This study will continue research designed to improve treatment outcomes for adolescent substance use disorders by integrating neuroscience- and behaviorally-based treatments.
- Trial name
- SMART (NCT02063984)
- Testing
- Intensive Outpatient Treatment (IOP) + Contingency Management (CM), Working Memory Training
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Nicotine Dependence, Tobacco Smoking
Effects of Intranasal Oxytocin on Cigarette Smoking
Socioemotional processing dysfunctions (i.e., disruptions in affective, cognitive, and neural processes that encode, interpret, and respond to socially and emotionally relevant stimuli) have been implicated in tobacco smoking and…
- Trial name
- NCT02595749
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Opioid-Related Disorders, Opiate Dependence
Treatment of Opioid Dependent Patients With Suboxone: Acceptability & Safety Data From Real Life Scenario (Study P05603)
The aim of this post marketing surveillance study is to investigate the retention rate after 12 months of drug dependence treatment with SUBOXONE® (buprenorphine plus naloxone) of opioid dependent patients under real life…
- Conditions
- Opioid-Related Disorders, Opiate Dependence, Drug Abuse
- Trial name
- NCT00723749
- Testing
- Buprenorphine/Naloxone
- Volunteers
- 384 people
- Sponsor
- Indivior Inc.
Alcohol Dependence, Bipolar Disorder
Acamprosate vs. Placebo in Bipolar Alcoholics
To conduct a double-blind, randomized, placebo-controlled outpatient clinical trial of acamprosate in individuals with alcohol dependence and bipolar disorder who are also receiving mood stabilizing medication.
- Trial name
- NCT00466661
- Testing
- Acamprosate
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Medical University of South Carolina
Prescription Drug Abuse (Not Dependent)
Influence of Medication on Functional Connectivity
This study will assess the effects of acute low-dose opioid administration on functional neuroimaging measures in healthy individuals
- Trial name
- NCT03612713
- Testing
- Oxycodone Medication First
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Yale University
Alcohol Abuse, Impulsive Behavior
Effects of Tolcapone on Decision Making and Alcohol Intake in Alcohol Users
The purpose of this study is to determine the effects of tolcapone on decision making and alcohol intake using a laboratory bar (on-site alcohol self-administration) in alcohol drinkers.
- Trial name
- NCT02740582
- Testing
- Tolcapone
- Where
- 2 sites in United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Jennifer Mitchell
Alcohol Use Disorder, Severe
Inpatient Single Dose Interventions for Alcohol Use Disorder
Every year, alcohol use disorder (AUD) generates millions of emergency department (ED) visits and hospital admissions, costing the U.S. health sector over $90 billion.
- Trial name
- NCT04562779
- Testing
- Naltrexone 380 MG, Ketamine Hydrochloride, Enhanced linkage
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Denver Health and Hospital Authority
Substance-Related Disorders
Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal
Opioid medications are commonly used for pain relief. When given over time, physical dependence can occur. This results in unpleasant side effects--such as agitation and nausea--if opioid medications are suddenly stopped.
- Trial name
- NCT00661674
- Testing
- Palonosetron, Hydroxyzine
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Stanford University
Alcoholism, Nicotine Dependence
Varenicline and Alcohol in Inpatient Addictions Program (IAP)
The overall hypothesis of this line of research is that varenicline will decrease alcohol consumption and tobacco use and will increase alcohol and tobacco abstinence rates.
- Trial name
- NCT01169610
- Testing
- Varenicline
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.